Clascoterone Keeps Gaining Ground in Acne
Two identical Phase 3 trials (plus a long‑term extension) randomized patients ≥12 years with moderate‑to‑severe acne to twice‑daily clascoterone 1% cream or vehicle for 12 weeks, with an optional open‑label extension of up to nine more months. Primary outcomes (IGA 0/1 and lesion counts) favored clascoterone by week 12, and clinically meaningful gains continued over time: facial treatment success reached about 30% at 12 months (truncal ~31.7% at 9 months). With a large pooled cohort and steady incremental benefit over the LTE, clascoterone looks like a durable, topical option to consider alongside your existing acne armamentarium.
Want details on responder characteristics, onset of effect, and how to combine clascoterone with other therapies? Read the full results to see where it might fit in your practice.
J Drugs Dermatol. 2024;23(1):1278-1283. doi:10.36849/JDD.7719
Blog write-up assisted by AI
